摘要
目的 观察低分子肝素 (L MWH)对肺心病心力衰竭的治疗效果。方法 12 0例肺心病心力衰竭患者随机分为 A、B两组。A组 (治疗组 )在常规治疗基础上加用低分子肝素 5 0 0 0 IU,每日 1次 ,皮下注射 ,10次为 1个疗程。 B组 (对照组 )除不加低分子肝素外 ,其余同 A组治疗。结果 A组全血黏度、血浆黏度、红细胞压积 (Hct)均明显下降 ,治疗前后相比有显著差异 (P<0 .0 1) ;而 B组治疗前后仅 Hct有显著差异 (P<0 .0 1) ,全血黏度、血浆黏度无显著差异 (P>0 .0 5 )。A、B两组疗效比较差异有显著性 (P<0 .0 5 )。结论 低分子肝素治疗肺心病心力衰竭有明显疗效 ,可改善血液高凝状态。
Objective To study the effect of LMWH on pulmonary heart disease heart failure.Methods 120 cases of PHDHF were divided into two groups (A and B). Patients in Group A were treated with subcutaneous LMWH 5,000 IU (i.h.) once daily for 10 days in addition to conventional therapy. Results Blood viscosity plasma viscosity Hct reduced significantly (P<0.01) in Group A after the treatment. In Group B only Hct reduced significantly (P<0.01). There was no difference of blood viscosity plasma viscosity between pre-treatment and post-treatment (P>0.05). The treatment effect was significantly different (P<0.05) between Group A and Group B.Conclusion LMWH has obvious treatment effects on PHDHF, and it can ameliorate the position of hypercoagulability.
出处
《临床肺科杂志》
2004年第1期37-38,共2页
Journal of Clinical Pulmonary Medicine
关键词
低分子肝素
肺心病心力衰竭
高凝状态
Lower-molecular-weight heparin (LMWH) Pulmonary heart disease heart failure (PHDHF) Position of hypercoagulability
